CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 7 filers reported holding CRISPR THERAPEUTICS AG in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $358,990 | -20.8% | 7,909 | -2.1% | 0.31% | -1.0% |
| Q2 2023 | $453,331 | +21.7% | 8,075 | -2.0% | 0.31% | -0.6% |
| Q1 2023 | $372,650 | +11.7% | 8,239 | +0.4% | 0.32% | +14.1% |
| Q4 2022 | $333,533 | -37.9% | 8,205 | -0.2% | 0.28% | -51.5% |
| Q3 2022 | $537,000 | +4.7% | 8,218 | -2.6% | 0.57% | +42.8% |
| Q2 2022 | $513,000 | -19.6% | 8,435 | +41.9% | 0.40% | -5.7% |
| Q3 2021 | $638,000 | -35.9% | 5,943 | -3.3% | 0.42% | -30.0% |
| Q2 2021 | $996,000 | -68.7% | 6,148 | +8097.3% | 0.61% | +20100.0% |
| Q1 2020 | $3,181,000 | -30.4% | 75 | 0.0% | 0.00% | -25.0% |
| Q4 2019 | $4,568,000 | +788.7% | 75 | -99.1% | 0.00% | -98.6% |
| Q1 1987 | $514,000 | – | 8,192 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |